A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Prior treatment

• Participants taking vitamin E (\>400 international units \[IU\]/day) must be on stable dose for at least 6 months prior to screening.
  • Other protocol-defined inclusion and exclusion criteria may apply.

Other illness

• Liver disorder other than MASH.
• Have type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus.

Lab values

• ALT or aspartate aminotransferase (AST) ≥250 units per liter (U/L).

Other

• History or evidence of hepatic decompensation.
• History or evidence of hepatocellular carcinoma.

• Males or non-pregnant females aged between 18 and 75 years (inclusive) at time of signing the informed consent form (ICF).
• Participants must have type 2 diabetes mellitus diagnosed at least 3 months before screening or at least 2 metabolic risk factors.
• Evidence of both cirrhosis and MASH etiology, either through a historical biopsy or a biopsy at Screening.
• Clinical diagnosis of cirrhosis based on the NIT algorithm.